GlassScriptPhysician profile
Sandip P Vasavada
NPI 1356306328
$262,832.02
in general payments reported to CMS, 2019-2025
24 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $29K · 2021: $5,906 · 2022: $48K · 2023: $55K · 2024: $64K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Travel and Lodging: $47K · Consulting Fee: $14K · Food and Beverage: $11K · Education: $89.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,481.67 |
| Travel and Lodging | $47,174.92 |
| Consulting Fee | $14,262.50 |
| Food and Beverage | $10,933.19 |
| Education | $89.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $168,047.59 | 2019-2025 | Interstim, Altaviva, Intellis Adaptivestim |
| Medtronic USA, INC. | $30,490.60 | 2019-2020 | |
| Bluewind Medical | $24,172.49 | 2020-2025 | Revi |
| Astellas Pharma INC | $21,158.17 | 2024 | Myrbetriq |
| Purdue Pharma L.P. | $6,600.00 | 2025 | |
| Provepharm INC. | $3,206.60 | 2024-2025 | Bludigo |
| Axonics, INC. | $2,273.58 | 2020-2024 | Axonics, Bulkamid |
| Allergan, INC. | $2,076.92 | 2019-2022 | |
| Abbvie INC. | $1,238.26 | 2022-2025 | Botox |
| Boston Scientific Corporation | $876.65 | 2020-2025 | Lynx System, Advantage System, Solyx Blue |
| Coloplast Corp | $763.87 | 2020-2025 | |
| Urovant Sciences INC | $372.09 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $359.73 | 2023 | Bard Urinary Drainage Bag |
| Rochester Medical Corporation | $356.76 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $268.12 | 2024-2025 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $151.60 | 2022-2024 | Desara |
| Antares Pharma, INC. | $138.35 | 2021 | |
| Laborie Medical Technologies Corp. | $119.60 | 2025 | |
| Astellas Pharma US INC | $82.65 | 2023 | |
| Contura, INC. | $42.44 | 2020 | |
| Becton, Dickinson and Company | $20.95 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| 180 Medical, INC. | $15.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,676,748.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandip Vasavada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.